Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083501 | 1.00 | MAOB (0.37) | MAOBCYP1A2TSHRNFKB1NPC1 | |
| SCHEMBL12083528 | 0.88 | TSHR (0.37) | TSHRNPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL12083533 | 0.80 | GAA (0.38) | NPC1RAB9AL3MBTL1KMT2AMEN1 | |
| SCHEMBL1845799 | 0.76 | BCAT2 (0.41) | TSHRNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1845798 | 0.76 | BCAT2 (0.41) | TSHRNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1845952 | 0.75 | AXL (0.41) | TSHRNPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL1845950 | 0.75 | AXL (0.41) | TSHRNPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL1847138 | 0.74 | KMT2A (0.48) | CYP1A2NPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL1847139 | 0.74 | KMT2A (0.48) | CYP1A2NPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL15936362 | 0.65 | NPC1 (0.35) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | claimed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | claimed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | claimed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | claimed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | claimed |
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | disclosed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| EP-2324006-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010029577-A2 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | GOKARAJU GANGA RAJU (IN) | 2010-03-18 | — | — | WO | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | BRAF, NRAS, TP53 | MAOB 1692/4885CYP1A2 1280/4885TSHR 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.